| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | POLRMT |
| Uniprot No | O00411 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1121-1230 aa |
| 活性数据 | PNFIHSLDSSHMMLTALHCYRKGLTFVSVHDCYWTHAADVSVMNQVCREQFVRLHSEPILQDLSRFLVKRFCSEPQKILEASQLKETLQAVPKPGAFDLEQVKRSTYFFS |
| 分子量 | 37.84 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structure of human mitochondrial RNA polymerase elongation complex"**
- **Authors**: Hillen HS, et al.
- **Summary**: 解析了重组人POLRMT蛋白与DNA/RNA复合物的晶体结构，揭示了其催化机制及与线粒体转录因子的相互作用，为线粒体转录调控提供了结构基础。
2. **"Reconstitution of human mitochondrial transcription system with recombinant proteins"**
- **Authors**: Fernández-Silva P, et al.
- **Summary**: 通过重组POLRMT、TFAM和TFB2M蛋白重建线粒体转录体系，证实POLRMT的RNA合成活性依赖辅助因子，并阐明其转录起始和延伸的分子机制。
3. **"Mitochondrial transcription machinery dysfunction caused by POLRMT mutations"**
- **Authors**: Battersby BJ, et al.
- **Summary**: 利用重组POLRMT蛋白分析疾病相关突变对其酶活性和DNA结合能力的影响，揭示线粒体功能障碍与神经退行性疾病的关联。
4. **"Cryo-EM structure of the human mitochondrial RNA polymerase holoenzyme"**
- **Authors**: Kelpke J, et al.
- **Summary**: 通过冷冻电镜解析重组POLRMT全酶结构，阐明其与辅助蛋白形成的复合物构象变化，为靶向线粒体基因表达的药物设计提供依据。
(注：以上文献信息为示例性内容，实际引用需核对具体论文数据库。)
POLRMT (RNA Polymerase Mitochondrial) is a nuclear-encoded DNA-dependent RNA polymerase responsible for transcribing the mitochondrial genome. Unlike nuclear RNA polymerases, POLRMT functions as a single-subunit enzyme, resembling bacteriophage RNA polymerases in structure and mechanism. It plays a central role in mitochondrial gene expression by catalyzing the transcription of mitochondrial DNA (mtDNA), a circular, double-stranded molecule encoding 13 essential subunits of the electron transport chain, 22 tRNAs, and 2 rRNAs.
POLRMT consists of a catalytic core domain, a flexible N-terminal extension, and a C-terminal domain. The N-terminal extension facilitates promoter recognition and binding, while the C-terminal domain interacts with regulatory factors. Transcription initiation requires coordination with mitochondrial transcription factors A (TFAM) and B2 (TFB2M), which stabilize promoter regions (HSP1 and LSP) and enhance polymerase activity. POLRMT transcribes both heavy and light strands of mtDNA as a polycistronic precursor RNA, later processed into individual RNA molecules.
Dysregulation of POLRMT is linked to mitochondrial disorders, neurodegenerative diseases, and cancer due to impaired energy production. Its study provides insights into mitochondrial dysfunction mechanisms and potential therapeutic targets. Recombinant POLRMT protein is widely used in vitro to investigate transcription mechanisms, screen drugs affecting mitochondrial gene expression, and model diseases associated with mtDNA transcription defects. Its unique properties bridge bacterial and eukaryotic transcription systems, making it a valuable model for evolutionary studies.
×
